Diagnostic Accuracy of a Novel Point-of-care Urine Lipoarabinomannan Assay for the Detection of Tuberculosis Among Adult Outpatients in Zambia: a Prospective Cross-sectional Study

Overview

Journal Eur Respir J

Specialty Pulmonary Medicine

Date 2021 Apr 30

PMID 33926972

Citations 11

Authors

Monde Muyoyeta

Andrew D Kerkhoff

Lophina Chilukutu

Emmanuel Moreau

Samuel G Schumacher

Morten Ruhwald

Affiliations

Soon will be listed here.

Abstract

Background: A novel, rapid, point-of-care urine-based lipoarabinomannan assay (Fujifilm SILVAMP TB LAM ("FujiLAM")) has previously demonstrated substantially higher sensitivity for tuberculosis (TB) compared with the commercially available Determine TB LAM assay using biobanked specimens. However, FujiLAM has not been prospectively evaluated using fresh urine specimens. Therefore, we determined the diagnostic accuracy of FujiLAM among HIV-positive and HIV-negative outpatients with presumptive TB in Zambia.

Methods: Adult (≥18 years old) presumptive TB patients presenting to two outpatient public health facilities in Lusaka were included. All patients submitted sputa samples for smear microscopy, Xpert MTB/RIF and mycobacterial culture, and urine samples for the FujiLAM assay. Microbiologically confirmed TB was defined by the detection of in sputum using culture; this served as the reference standard to assess the diagnostic accuracy of FujiLAM.

Results: 151 adults with paired sputum microbiological tests and urine FujiLAM results were included; 45% were HIV-positive. Overall, 34 out of 151 (23%) patients had culture-confirmed pulmonary TB. The overall sensitivity and specificity of FujiLAM was 77% (95% CI 59-89%) and 92% (95% CI 86-96%), respectively. FujiLAM's sensitivity among HIV-positive patients was 75% (95% CI 43-95%) compared with 75% (95% CI 51-91%) among HIV-negative patients. The sensitivity of FujiLAM in patients with smear-positive, confirmed pulmonary TB was 87% (95% CI 60-98%) compared with 68% (95% CI 43-87%) among patients with smear-negative, confirmed pulmonary TB.

Conclusions: FujiLAM demonstrated high sensitivity for the detection of TB among both HIV-positive and HIV-negative adults, and also demonstrated good specificity despite the lack of systematic extrapulmonary sampling to inform a comprehensive microbiological reference standard.

Citing Articles

Assessing the accuracy of the updated Fujifilm SILVAMP TB LAM II assay between lot numbers.

Chikamatsu K, Shimomura Y, Osugi A, Mitarai S IJTLD Open. 2025; 2(2):96-100.

PMID: 39959407 PMC: 11827673. DOI: 10.5588/ijtldopen.24.0449.

Immunoassay with Novel Paired Antibodies for Detection of Lipoarabinomannan in the Pleural Fluid and Plasma of Patients with Tuberculous Pleurisy.

Yan Z, Wang J, Pang Y, Wang X, Yi L, Wei P Microorganisms. 2023; 11(9).

PMID: 37764103 PMC: 10535579. DOI: 10.3390/microorganisms11092259.

Advanced HIV disease: A review of diagnostic and prophylactic strategies.

Lehman A, Ellis J, Nalintya E, Bahr N, Loyse A, Rajasingham R HIV Med. 2023; 24(8):859-876.

PMID: 37041113 PMC: 10642371. DOI: 10.1111/hiv.13487.

User perspectives and preferences on a novel TB LAM diagnostic (Fujifilm SILVAMP TB LAM)-a qualitative study in Malawi and Zambia.

Herrmann Y, Lainati F, Castro M, Mwamba C, Kumwenda M, Muyoyeta M PLOS Glob Public Health. 2023; 2(7):e0000672.

PMID: 36962216 PMC: 10021253. DOI: 10.1371/journal.pgph.0000672.

Novel FujiLAM assay to detect tuberculosis in HIV-positive ambulatory patients in four African countries: a diagnostic accuracy study.

Huerga H, Bastard M, Lubega A, Akinyi M, Antabak N, Ohler L Lancet Glob Health. 2022; 11(1):e126-e135.

PMID: 36521944 PMC: 9747168. DOI: 10.1016/S2214-109X(22)00463-6.

References

Bulterys M, Wagner B, Redard-Jacot M, Suresh A, Pollock N, Moreau E . Point-Of-Care Urine LAM Tests for Tuberculosis Diagnosis: A Status Update. J Clin Med. 2020; 9(1). PMC: 7020089. DOI: 10.3390/jcm9010111. View

Singhroy D, Maclean E, Kohli M, Lessem E, Branigan D, England K . Adoption and uptake of the lateral flow urine LAM test in countries with high tuberculosis and HIV/AIDS burden: current landscape and barriers. Gates Open Res. 2020; 4:24. PMC: 7059561. DOI: 10.12688/gatesopenres.13112.2. View

Bjerrum S, Schiller I, Dendukuri N, Kohli M, Nathavitharana R, Zwerling A . Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV. Cochrane Database Syst Rev. 2019; 10:CD011420. PMC: 6802713. DOI: 10.1002/14651858.CD011420.pub3. View

Kerkhoff A, Sossen B, Schutz C, Reipold E, Trollip A, Moreau E . Diagnostic sensitivity of SILVAMP TB-LAM (FujiLAM) point-of-care urine assay for extra-pulmonary tuberculosis in people living with HIV. Eur Respir J. 2019; 55(2). PMC: 7002975. DOI: 10.1183/13993003.01259-2019. View

Albert H, Nathavitharana R, Isaacs C, Pai M, Denkinger C, Boehme C . Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better?. Eur Respir J. 2016; 48(2):516-25. PMC: 4967565. DOI: 10.1183/13993003.00543-2016. View

Broger T, Sossen B, du Toit E, Kerkhoff A, Schutz C, Reipold E . Novel lipoarabinomannan point-of-care tuberculosis test for people with HIV: a diagnostic accuracy study. Lancet Infect Dis. 2019; 19(8):852-861. PMC: 6656794. DOI: 10.1016/S1473-3099(19)30001-5. View

Broger T, Muyoyeta M, Kerkhoff A, Denkinger C, Moreau E . Tuberculosis test results using fresh versus biobanked urine samples with FujiLAM. Lancet Infect Dis. 2019; 20(1):22-23. DOI: 10.1016/S1473-3099(19)30684-X. View

Sigal G, Pinter A, Lowary T, Kawasaki M, Li A, Mathew A . A Novel Sensitive Immunoassay Targeting the 5-Methylthio-d-Xylofuranose-Lipoarabinomannan Epitope Meets the WHO's Performance Target for Tuberculosis Diagnosis. J Clin Microbiol. 2018; 56(12). PMC: 6258851. DOI: 10.1128/JCM.01338-18. View

Hunter S, Gaylord H, Brennan P . Structure and antigenicity of the phosphorylated lipopolysaccharide antigens from the leprosy and tubercle bacilli. J Biol Chem. 1986; 261(26):12345-51. View

10.

Broger T, Nicol M, Sigal G, Gotuzzo E, Zimmer A, Surtie S . Diagnostic accuracy of 3 urine lipoarabinomannan tuberculosis assays in HIV-negative outpatients. J Clin Invest. 2020; 130(11):5756-5764. PMC: 7598043. DOI: 10.1172/JCI140461. View

11.

Broger T, Nicol M, Szekely R, Bjerrum S, Sossen B, Schutz C . Diagnostic accuracy of a novel tuberculosis point-of-care urine lipoarabinomannan assay for people living with HIV: A meta-analysis of individual in- and outpatient data. PLoS Med. 2020; 17(5):e1003113. PMC: 7194366. DOI: 10.1371/journal.pmed.1003113. View

12.

Kandhakumari G, Stephen S . Evaluation of a new rapid kit, BD MGIT TBc identification test for confirmation of complex. Indian J Pathol Microbiol. 2017; 60(2):243-246. DOI: 10.4103/IJPM.IJPM_695_15. View

13.

Dorman S, Schumacher S, Alland D, Nabeta P, Armstrong D, King B . Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. Lancet Infect Dis. 2017; 18(1):76-84. PMC: 6168783. DOI: 10.1016/S1473-3099(17)30691-6. View